Platelet-Rich Plasma (PRP) As A New Approach And Promising Therapy In Patients With Alopecia Areata
DOI:
https://doi.org/10.36408/mhjcm.v10i1.818Keywords:
platelet-rich plasma, alopecia areata, hair lossAbstract
Background: Alopecia areata (AA) is a non-scarring, autoimmune, inflammatory condition that causes well-defined areas of hair loss on the scalp and/or body. A new biotechnology called platelet-rich plasma (PRP) was developed as a result of increased interest in tissue engineering and cell-based therapies. This therapy is defined as an autologous, non-allergic preparation of platelets in concentrated plasma. Study aimed to evaluate the effect of PRP treatment in alopecia areata.
Case: This study included 3 patients complaining of multiple patchy alopecia areata. They were treated with combination of PRP therapy, topical fluocinolone acetonide 0.025% cream, minoxidil 2 and 5%, and ketoconazole 2% scalp solution. One patient was also treated with intralesional triamcinolone acetonide injections. PRP was injected intradermally every 4 weeks and final monitoring was conducted after 4-6 sessions. Evaluation and follow up results were determined using photographic monitoring as well as patient’s satisfaction.
Results: Administration of autologous PRP had significance hair regrowth in all three patients in this study. PRP treatment sessions varied from 3 to 6 sessions. However, significance outcomes in these patients were established after 3 sessions of PRP treatment, while the best results were obtained after 4-6 sessions of PRP treatment. No major side effects was reported.
Conclusion: PRP is effective in promoting hair growth. PRP treatment for alopecia areata is safe, easy to perform, and can achieve patient’s satisfaction, without any major adverse effects. However, further research on standardized protocol of PRP methods are needed.
Downloads
References
- Fayed HA, Elsaied MA, Faraj MR. Evaluation of Platelet-Rich Plasma in Treatment of Alopecia Areata: A Placebo-Controlled Study. J Egypt Women Dermatol Soc. 2018;15:100-5.
- Ciptasari NEW. Role of PRP (platelet-rich plasma) in alopecia areata: A literature review. Bali Med J. 2020;9(3):731-6.
- Cervantes J, Perper M, Wong LL, et al. Effectiveness of Platelet-Rich Plasma for Androgenetic Alopecia: A Review of the Literature. Skin Appendage Diord. 2018;4:1-11.
- Elsayed M, Al Otaibi L, Quraishy N, Yusufali A. A Novel Hope for Alopecia Totalis Patients: Case Report. Dubai Med J. 2020;3:150-3.
- Elshafy RAA, Khalifa NA, Besher RM, Ebrahim HM, Mawla MYMA. Alopecia Areata: An Overview of the Disease and its Genetic Basis: Review Article. Egypt J Hosp Med. 2022;88:2897-903.
- Ramos PM, Anzai A, Duque-Estrada B, Melo DF, Sternberg F, Santos LDN, Alves LD. Consensus on the treatment of alopecia areata – Brazilian Society of Dermatology. An Bras Dermatol. 2020;95(S1):39-52.
- Khalid AA. Medical Treatment of Alopecia. In: Ahmad M. Alopecia. IntechOpen. 2018:55-72. Available from: https://www.intechopen.com/books/alopecia/medical-treatment-of-alopecia
- Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and Its Use in Hair Disorders: A Review. Drug Des Devel Ther. 2019;13:2777-86.
- Choi N, Shin S, Song SU, et al. Minoxidil Promotes Hair Growth Through Stimulation od Growth Factor Release from Adipose-Derived Stem Cells. Int J Mol Sci. 2018;19(691):1-15.
- El-Garf, Mohie M, Salah E. Trichogenic effect of topical ketoconazole versus minoxidil 2% in female pattern hair loss: a clinical and trichoscopic evaluation. Biomed Dermatol. 2019;3:1-8.
- Singh GK, Pathania V, Beniwal NS, et al. Platelet Rich Plasma, 5% Minoxidil Lotion and Oral Dutasteride Versus 5% Minoxidil Lotion and Oral Dutasteride in Male Androgenetic Alopecia: A Pilot Study in Routine Clinical Setting. Indian J Clin Dermatol. 2019;2(3):78-83.
Additional Files
Published
How to Cite
Issue
Section
Citation Check
License
Copyright (c) 2023 Elva Kadarhadi, Imelda Gunawan, Holy Ametati, Diah Adriani Malik, Muji Rahayu
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Copyrights Notice
Copyrights:
Researchers publishing manuscrips at Medica Hospitalis: Journal of Clinical Medicine agree with regulations as follow:
Copyrights of each article belong to researchers, and it is likewise the patent rights
Researchers admit that Medica Hospitalia: Journal of Clinical Medicine has the right of first publication
Researchers may submit manuscripts separately, manage non exclusive distribution of published manuscripts into other versions (such as: being sent to researchers’ institutional repository, publication in the books, etc), admitting that manuscripts have been firstly published at Medica Hospitalia: Journal of Clinical Medicine
License:
Medica Hospitalia: Journal of Clinical Medicine is disseminated based on provisions of Creative Common Attribution-Share Alike 4.0 Internasional It allows individuals to duplicate and disseminate manuscripts in any formats, to alter, compose and make derivatives of manuscripts for any purpose. You are not allowed to use manuscripts for commercial purposes. You should properly acknowledge, reference links, and state that alterations have been made. You can do so in proper ways, but it does not hint that the licensors support you or your usage.
